EUVIMEDEUVIMED entdecken
Fallbericht

Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog

Dongheon Shin, Chaerin Kim, Yeon Chae, Taesik Yun, Byeong-Teck Kang, Kyung-Mee Park, Hakhyun Kim

Journal of the American Animal Hospital Association · 2024

DOI: 10.5326/jaaha-ms-7463 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of the American Animal Hospital Association, 2024. Verfasst von Dongheon Shin und 6 weiteren Autor:innen. Beteiligte Einrichtung: From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National Univers…. Hauptthemen laut MEDLINE: Sorafenib, Dog Diseases, Carcinoma, Transitional Cell, Antineoplastic Agents. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most urinary bladder (UB) tumors are malignant, and transitional cell carcinoma (TCC) is the most common neoplasm affecting the UB in dogs. Sorafenib may be a potential therapeutic agent for canine TCC. A 12 yr old spayed female Maltese dog weighing 3.6 kg and with a history of hematuria was referred for a suspected UB tumor. Abdominal ultrasonography revealed a UB mass attached to the cranioventral wall. The remaining abdominal examinations, including that of the lymph nodes, were unremarkable. Ultrasound-guided traumatic catheterization of the UB mass was performed, and the cytological evaluation of the UB mass indicated TCC. Excision was performed by partial cystectomy, and histopathology confirmed TCC, although the tumor had infiltrated the surgical margins. A chemosensitivity assay was conducted using tissue from the excised tumor. Sorafenib tosylate, a tyrosine kinase inhibitor, showed the greatest effect in the chemosensitivity assay. Therefore, adjuvant chemotherapy with sorafenib tosylate and piroxicam was administered postoperatively. The dog lived without any clinical signs, including hematuria or tumor relapse, for more than 2 yr after the surgery. This is the first report of successful long-term management of TCC with sorafenib tosylate in a dog.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibDog DiseasesCarcinoma, Transitional CellAntineoplastic AgentsUrinary Bladder NeoplasmsDogsAnimalsFemalePhenylurea Compounds

Substanzen

SorafenibAntineoplastic AgentsPhenylurea Compounds

Autor:innen und Institutionen

  • From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
  • Laboratory of Veterinary Surgery/Ophthalmology (K.-M.P), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.

Zitieren

APA

Shin, D., Kim, C., Chae, Y., Yun, T., Kang, B. T., Park, K. M., & Kim, H. (2024). Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog. Journal of the American Animal Hospital Association. https://doi.org/10.5326/jaaha-ms-7463

Vancouver

Shin D, Kim C, Chae Y, Yun T, Kang BT, Park KM, et al. Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog. Journal of the American Animal Hospital Association. 2024. doi:10.5326/jaaha-ms-7463

BibTeX
@article{Shin2024,
  author = {Shin, Dongheon and Kim, Chaerin and Chae, Yeon and Yun, Taesik and Kang, Byeong-Teck and Park, Kyung-Mee and Kim, Hakhyun},
  title = {Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog},
  journal = {Journal of the American Animal Hospital Association},
  year = {2024},
  doi = {10.5326/jaaha-ms-7463}
}
Kostenlos starten →